This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-56022473

Johnson & Johnson

Drug Names(s): CSL362, CSL-362

Description: CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.

Deal Structure: Xencor and CSL
In February 2013, Xencor announced that it has entered into an antibody optimization collaboration with CSL. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates into development and ultimately commercialization which incorporate Xencor's XmAb technology. In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.

Janssen and CSL
In December 2013, CSL announced an agreement with Janssen that grants an exclusive worldwide license to develop and commercialise CSL362. Under the...See full deal structure in Biomedtracker

Partners: CSL Limited Xencor, Inc.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug